NAD+ kinase as a therapeutic target in cancer

Clinical Cancer Research

Volumn 22, Issue 21, 2016, Pages 5189-5195

  Tedeschi, Philip M ^a   Bansal, Nitu ^a   Kerrigan, John E ^a   Abali, Emine E ^a   Scotto, Kathleen W ^a   Bertino, Joseph R ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 AMINONICOTINAMIDE; ANTINEOPLASTIC AGENT; BENZAMIDE ADENINE NUCLEOSIDE; DIHYDROFOLATE REDUCTASE; DOCETAXEL; GEMCITABINE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GLUTATHIONE; IRINOTECAN; METHOTREXATE; NICOTINAMIDE ADENINE DINUCLEOTIDE KINASE; PRODRUG; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; THIONICOTINAMIDE; THIOREDOXIN; UNCLASSIFIED DRUG; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; PHOSPHOTRANSFERASE;

B CELL LYMPHOMA; CANCER INHIBITION; COLON CANCER; CYTOPLASM; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG TARGETING; HUMAN; LYMPHOMA; MITOCHONDRION; NEUROTOXICITY; NONHUMAN; NONSENSE MUTATION; OXIDATIVE STRESS; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; REVIEW; TUMOR REGRESSION; TUMOR XENOGRAFT; ANIMAL; DRUG EFFECTS; METABOLISM; NEOPLASM; OXIDATION REDUCTION REACTION;

ANIMALS; HUMANS; NAD; NADP; NEOPLASMS; OXIDATION-REDUCTION; OXIDATIVE STRESS; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); REACTIVE OXYGEN SPECIES;

EID: 84994624526     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-1129     Document Type: Review

References (44)

1. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer 2011;11:85-95.
2. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029-33.
3. Jiang P, Du W, Mancuso A, Wellen KE, Yang X. Reciprocal regulation of p53 and malic enzymes modulates metabolism and senescence. Nature 2013;493:689-93.
4. Jiang P, Du W, Wang X, Mancuso A, Gao X, Wu M, et al. p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. Nat Cell Biol 2011;13:310-6.
5. Anastasiou D, Poulogiannis G, Asara JM, Boxer MB, Jiang JK, Shen M, et al. Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science 2011;334:1278-83.
6. Ying W. NAD+/NADH and NADP+/NADPH in cellular functions and cell death: regulation and biological consequences. Antioxid Redox Signal 2008;10:179-206.
7. Boonstra J, Post JA. Molecular events associated with reactive oxygen species and cell cycle progression in mammalian cells. Gene 2004;337: 1-13.
8. Schafer FQ, Buettner GR. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med 2001;30:1191-212.
9. Alexandre J, Nicco C, Chereau C, Laurent A, Weill B, Goldwasser F, et al. Improvement of the therapeutic index of anticancer drugs by the superoxide dismutase mimic mangafodipir. J Natl Cancer Inst 2006;98: 236-44.
10. Fei ZH, Wu K, Chen YL, Wang B, Zhang SR, Ma SL. Capilliposide isolated from Lysimachia capillipes Hemsl. induces ROS generation, cell cycle arrest, and apoptosis in human nonsmall cell lung cancer cell lines. Evid Based Complement Alternat Med 2014;2014:497456.
11. Qian C, Wang Y, Zhong Y, Tang J, Zhang J, Li Z, et al. Wogonin-enhanced reactive oxygen species-induced apoptosis and potentiated cytotoxic effects of chemotherapeutic agents by suppression Nrf2-mediated signaling in HepG2 cells. Free Radic Res 2014;48:607-21.
12. Li X, Fang P, Mai J, Choi ET, Wang H, Yang XF. Targeting mitochondrial reactive oxygen species as novel therapy for inflammatory diseases and cancers. J Hematol Oncol 2013;6:19.
13. Wondrak GT. Redox-directed cancer therapeutics: molecular mechanisms and opportunities. Antioxid Redox Signal 2009;11:3013-69.
14. Buldak RJ, Buldak L, Kukla M, Gabriel A, Zwirska-Korczala K. Significance of selected antioxidant enzymes in cancer cell progression. Pol J Pathol 2014;65:167-75.
15. Liu YC, Li F, Handler J, Huang CR, Xiang Y, Neretti N, et al. Global regulation of nucleotide biosynthetic genes by c-Myc. PLoS One 2008;3: e2722.
16. Kornberg A, Pricer WE Jr. On the structure of triphosphopyridine nucleotide. J Biol Chem 1950;186:557-67.
17. Apps DK. Pigeon-liver NAD kinase. The structural and kinetic basis of regulation of NADPH. Eur J Biochem 1975;55:475-83.
18. Bulygina ER, Telepneva VI. [Isolation of NAD-kinase from pigeon heart]. Biokhimiia 1980;45:2019-27.
19. Butler JR, McGuinness ET. Candida utilis NAD+ kinase: purification, properties and affinity gel studies. Int J Biochem 1982;14:839-44.
20. Tseng YM, Harris BG, Jacobson MK. Isolation and characterization of yeast nicotinamide adenine dinucleotide kinase. Biochim Biophys Acta 1979;568:205-14.
21. Lerner F, Niere M, Ludwig A, Ziegler M. Structural and functional characterization of human NAD kinase. Biochem Biophys Res Commun 2001;288:69-74.
22. Ohashi K, Kawai S, Murata K. Identification and characterization of a human mitochondrial NAD kinase. Nat Commun 2012;3:1248.
23. Zhang R. MNADK, a long-awaited human mitochondrion-localized NAD kinase. J Cell Physiol 2015;230:1697-701.
24. Takahara K, Kasajima I, Takahashi H, Hashida SN, Itami T, Onodera H, et al. Metabolome and photochemical analysis of rice plants overexpressing Arabidopsis NAD kinase gene. Plant Physiol 2010;152:1863-73.
25. Takahashi H, Takahara K, Hashida SN, Hirabayashi T, Fujimori T, Kawai-Yamada M, et al. Pleiotropic modulation of carbon and nitrogen metabolism in Arabidopsis plants overexpressing the NAD kinase2 gene. Plant Physiol 2009;151:100-13.
26. Waller JC, Dhanoa PK, Schumann U, Mullen RT, Snedden WA. Subcellular and tissue localization of NAD kinases from Arabidopsis: compartmentalization of de novo NADP biosynthesis. Planta 2010;231:305-17.
27. Shi F, Li Y, Li Y, Wang X. Molecular properties, functions, and potential applications of NAD kinases. Acta Biochim Biophys Sin 2009;41:352-61.
28. Wang Y, San KY, Bennett GN. Improvement of NADPH bioavailability in Escherichia coli by replacing NAD(+)-dependent glyceraldehyde-3-phosphate dehydrogenase GapA with NADP (+)-dependent GapB from Bacillus subtilis and addition of NAD kinase. J Ind Microbiol Biotechnol 2013;40:1449-60.
29. Cui YY, Ling C, Zhang YY, Huang J, Liu JZ. Production of shikimic acid from Escherichia coli through chemically inducible chromosomal evolution and cofactor metabolic engineering. Microb Cell Fact 2014;13:21.
30. Li ZJ, Cai L, Wu Q, Chen GQ. Overexpression of NAD kinase in recombinant Escherichia coli harboring the phbCAB operon improves poly(3-hydroxybutyrate) production. Appl Microbiol Biotechnol 2009;83: 939-47.
31. Bi J, Wang H, Xie J. Comparative genomics of NAD(P) biosynthesis and novel antibiotic drug targets. J Cell Physiol 2011;226:331-40.
32. Petrelli R, Sham YY, Chen L, Felczak K, Bennett E, Wilson D, et al. Selective inhibition of nicotinamide adenine dinucleotide kinases by dinucleoside disulfide mimics of nicotinamide adenine dinucleotide analogues. Bioorg Med Chem 2009;17:5656-64.
33. Petrelli R, Felczak K, Cappellacci L. NMN/NaMN adenylyltransferase (NMNAT) and NAD kinase (NADK) inhibitors: chemistry and potential therapeutic applications. Curr Med Chem 2011;18:1973-92.
34. Tedeschi PM, Lin H, Gounder M, Kerrigan JE, Abali EE, Scotto K, et al. Suppression of cytosolic NADPH pool by thionicotinamide increases oxidative stress and synergizes with chemotherapy. Mol Pharmacol 2015;88:720-7.
35. Pollak N, Niere M, Ziegler M. NAD kinase levels control the NADPH concentration in human cells. J Biol Chem 2007;282:33562-71.
36. Houten SM, Denis S, Te Brinke H, Jongejan A, van Kampen AH, Bradley EJ, et al. Mitochondrial NADP(H) deficiency due to a mutation in NADK2 causes dienoyl-CoA reductase deficiency with hyperlysinemia. Hum Mol Genet 2014;23:5009-16.
37. Tsang YH, Dogruluk T, Tedeschi PM, Wardwell-Ozgo J, Lu H, Espitia M, et al. Funtional annotation of rare gene aberration drivers of pancreatic cancer. Nat Commun 2016;7:10500.
38. Pankiewicz KW, Watanabe KA, Lesiak-Watanabe K, Goldstein BM, Jayaram HN. The chemistry of nicotinamide adenine dinucleotide (NAD) analogues containing C-nucleosides related to nicotinamide riboside. Curr Med Chem 2002;9:733-41.
39. Roussel B, Johnson-Farley N, Kerrigan JE, Scotto KW, Banerjee D, Felczak K, et al. A second target of benzamide riboside: dihydrofolate reductase. Cancer Biol Ther 2012;13:1290-8.
40. Hsieh YC, Tedeschi P, Adebisi Lawal R, Banerjee D, Scotto K, Kerrigan JE, et al. Enhanced degradation of dihydrofolate reductase through inhibition of NAD kinase by nicotinamide analogs. Mol Pharmacol 2013;83:339-53.
41. Herken H, Meyer-Estorf G, Halbhubner K, Loos D. Spastic paresis after 6-aminonicotinamide: metabolic disorders in the spinal cord and electromyographically recorded changes in the hind limbs of rats. Naunyn Schmiedebergs Arch Pharmacol 1976;293:245-55.
42. Herter FP, Weissman SG, Thompson HG Jr, Hyman G, Martin DS. Clinical experience with 6-aminonicotinamide. Cancer Res 1961;21: 31-7.
43. Koutcher JA, Alfieri AA, Matei C, Meyer KL, Street JC, Martin DS. Effect of 6-aminonicotinamide on the pentose phosphate pathway: 31P NMR and tumor growth delay studies. Magn Reson Med 1996;36: 887-92.
44. PDB ID: 3PFN. Wang H, Tempel W, Wernimont AK, Tong Y, Guan X, Shen Y, et al. Structural Genomics Consortium. Crystal structure of human NAD kinase.